News & Updates

Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.

Antihypertensive therapy (AHT) may be used safely during the COVID-19 pandemic, as no evidence suggest that it can increase the risk of SARS-CoV-2 infection or death, according to a UK study. In addition, most classes of antihypertensives are negatively associated with COVID-19 diagnosis.

Adding duloxetine to usual care does not appear to produce significant relief from chronic osteoarthritis pain as compared with usual care alone, a study has found.

Use of cardiovascular medications does not lead to poor COVID-19 clinical outcomes among high-risk patients, such as those with hypertension, according to a study.

Vaccines against SARS-CoV-2 has a safety profile that is similar in patients with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) and those with noninflammatory RMD (NI-RMD), according to a study. The vaccines are well tolerated with rare reports of I-RMD flare and serious adverse events.

Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.